PMGC Holdings (ELAB) EBT Margin (2022 - 2026)

PMGC Holdings' (ELAB) quarterly EBT Margin came in at 331.11% in Q2 2026, up 39.69% quarter-over-quarter from 549.04% in Q1 2026.

Analysis

PMGC Holdings (ELAB) EBT Margin (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed EBT Margin across 5 years of filings, most recently posting 331.11% for Q2 2026.

In Q2 2026, EBT Margin changed N/A year-over-year to 331.11%; the TTM figure through Jun 2026 stood at 503.6% (changed N/A YoY), while the FY2025 annual figure was 1415.72%, changed N/A from the prior year.
EBT Margin came in at 331.11% for Q2 2026 at PMGC Holdings, up from 549.04% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 108.61% in Q3 2022 to a low of 842.23% in Q4 2025.
Average EBT Margin over 5 years is 374.03%, with a median of 297.28% recorded in 2024.
Year-over-year, EBT Margin surged 31514 bps in 2024 and sank 52594 bps in 2025.
Over 5 years, EBT Margin stood at 177.86% in 2022, then climbed by 12 bps to 155.69% in 2023, then slumped by 91 bps to 297.28% in 2024, then plunged by 183 bps to 842.23% in 2025, then jumped by 61 bps to 331.11% in 2026.
Per Business Quant data, the three most recent EBT Margin figures were 331.11% in Q2 2026, 549.04% in Q1 2026, and 842.23% in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	207.26 Bn	193.27 Bn	7.24 Bn	27.53%
2	Gilead Sciences	179.66 Bn	176.48 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	131.52 Bn	123.67 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	81.77 Bn	73.78 Bn	3.93 Bn	35.61%
5	Argenx Se	61.15 Bn	55.97 Bn	1.37 Bn	35.78%
6	Moderna	53.55 Bn	48.41 Bn	52.00 Mn	-528.97%
7	Alnylam Pharmaceuticals	33.38 Bn	30.07 Bn	992.69 Mn	13.77%
8	Biogen	31.68 Bn	30.40 Bn	1.96 Bn	4.84%
9	Roivant Sciences	29.12 Bn	29.12 Bn	1.16 Mn	-20,427.46%
10	PMGC Holdings	2.29 Mn	-16.50 Mn	385,691.00	-331.11%

Historic Data

Download Data